Storia in 4 fonti

Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug

Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo12 h fa

Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug

Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.

originale

Timeline cronologica

lunedì 27 luglio 2026·statnews.com
Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug
Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.
lunedì 27 luglio 2026·medpagetoday.com
FDA Scientists Raise Questions About Duchenne Drug
Agency says deramiocel did not meet phase III trial endpoints, contrary to reported data

Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug

Confronto fonti

Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug

Timeline cronologica

Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug

FDA Scientists Raise Questions About Duchenne Drug

Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

FDA Scientists Raise Questions About Duchenne Drug

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm